SecBot SecBot
SC 13G/A ·Filed Nov 6, 2026

PCVX

Vaxcyte, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed10d 12h ago SEC0001897612-26-000700
Passive stake amendment
Actionable Insight • Neutral

Monitor whether T. Rowe Price files a 13D (activist conversion) or continues to adjust its position in future 13G amendments. The passive nature of this filing suggests no imminent activist intent.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$63.89
T+0 close · Nov 6, 2026 · via day close
Latest settled
−0.81%
T+5 · $63.37
Vs SPY
−3.41%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $63.89entry
  2. T+1 · 8d ago +5.70%α +3.33% · $67.53
  3. T+5 · 4d ago −0.81%α −3.41% · $63.37
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

T. Rowe Price Investment Management filed an amended Schedule 13G disclosing a 9.6% passive stake in Vaxcyte as of September 30, 2026, up from a prior filing. The increase in a passive holding is neutral; the filing follows positive Phase 3 data for VAX-31 and a $1.1B capital raise reported two days earlier.

Key Financial Metrics

Stake
9.6%
Investor
T. Rowe Price Investment Management, Inc.
Investor Type
mutual fund

Key Facts

  • T. Rowe Price Investment Management reported beneficial ownership of 14,312,368 shares of Vaxcyte common stock as of September 30, 2026.
  • The stake represents 9.6% of shares outstanding.
  • This is an amendment (SC 13G/A) updating a prior passive stake filing.
  • The filing certifies the securities were acquired and held in the ordinary course of business, not to influence control.

Financial Impact

T. Rowe Price holds 14,312,368 shares, 9.6% of Vaxcyte, valued at approximately $986M based on the $10.3B market cap snapshot.

ownership_percentage

Risk Factors

  • A future conversion to Schedule 13D could signal activist intent, though not indicated here.
  • A reduction below 5% in a future filing could be viewed as loss of institutional confidence.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001897612-26-000700
Document: 0001897612-26-000700-index.html0001897612-26-000700
Document: 0001897612-26-000700.txt0001897612-26-000700

Track record

29 reports on PCVX

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +10.87% at T+5 after the Oct 8, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.40 Now $61.61 −1.27% settles Dec 15
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $64.69 Now $61.61 −4.76% settles Dec 11
  3. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $63.89 Now $61.61 −3.57% settles Dec 7
  4. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Viewing Entry $63.89 Now $61.61 −3.57% settles Dec 7
  5. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
  6. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $61.92 Now $61.61 −0.50% settles Dec 4
  7. Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
  8. Nov 2, 202614d ago 144 Neutral 2/10 Entry $60.81 Now $61.61 +1.32% settles Dec 2
  9. Oct 9, 20265w ago 8-K Bearish 6/10 Entry $70.65 to $67.53 Now $61.61 +12.80% ▲ +4.42% +1.15% vs SPY
  10. Oct 8, 20265w ago 424B5 Bearish 6/10 Entry $71.38 to $63.89 Now $61.61 +13.69% ▲ +10.49% +4.93% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens Wed (10h 15m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026